{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T13:32:19Z","timestamp":1785850339282,"version":"3.56.0"},"reference-count":26,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","redjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.ijrobp.2020.12.020","type":"journal-article","created":{"date-parts":[[2020,12,17]],"date-time":"2020-12-17T18:04:12Z","timestamp":1608228252000},"page":"1263-1270","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Hypofractionated Radiation Therapy to the Prostate Bed With Intensity-Modulated Radiation Therapy (IMRT): A Phase 2 Trial"],"prefix":"10.1016","volume":"109","author":[{"given":"Elton Trigo Teixeira","family":"Leite","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clarissa Cerchi Angotti","family":"Ramos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor Augusto Bertotti","family":"Ribeiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernardo Peres","family":"Salvajoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William Carlos","family":"Nahas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00e3o Victor","family":"Salvajoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Ynoe Moraes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2020.12.020_bib1","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/pcan.2017.5","article-title":"Contemporary management of men with high-risk localized prostate cancer in the United States","volume":"20","author":"Weiner","year":"2017","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.ijrobp.2020.12.020_bib2","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1097\/COC.0000000000000358","article-title":"Adjuvant radiotherapy versus wait-and-see strategy for pathologic T3 or margin-positive prostate cancer","volume":"41","author":"Shaikh","year":"2018","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2020.12.020_bib3","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1016\/S1470-2045(20)30456-3","article-title":"Adjuvant radiotherapy versus early salvage radiotherapy following radical prostatectomy (TROG 08.03\/ANZUP RAVES): A randomised, controlled, phase 3, non-inferiority trial","volume":"21","author":"Kneebone","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2020.12.020_bib4","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/S0140-6736(20)31553-1","article-title":"Timing of radiotherapy after radical prostatectomy (RADICALS-RT): A randomised, controlled phase 3 trial","volume":"396","author":"Parker","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.ijrobp.2020.12.020_bib5","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/S1470-2045(20)30454-X","article-title":"Adjuvant radiotherapy versus early salvage radiotherapy plus short-term androgen deprivation therapy in men with localised prostate cancer after radical prostatectomy (GETUG-AFU 17): A randomised, phase 3 trial","volume":"21","author":"Sargos","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2020.12.020_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(20)31952-8","article-title":"Adjuvant or early salvage radiotherapy for the treatment of localised and locally advanced prostate cancer: A prospectively planned systematic review and meta-analysis of aggregate data","author":"Vale","year":"20203961422","journal-title":"Lancet"},{"key":"10.1016\/j.ijrobp.2020.12.020_bib7","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/j.ijrobp.2019.01.006","article-title":"Utilization of salvage radiation therapy for biochemical recurrence after radical prostatectomy","volume":"104","author":"Hawken","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2020.12.020_bib8","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.euf.2017.10.011","article-title":"Conventional versus hypofractionated radiation therapy for localized prostate cancer: A meta-analysis of randomized noninferiority trials","volume":"5","author":"Royce","year":"2019","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.ijrobp.2020.12.020_bib9","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ctrv.2017.11.004","article-title":"Hypofractionated radiotherapy for prostate cancer in the postoperative setting: What is the evidence so far?","volume":"62","author":"Picardi","year":"2018","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ijrobp.2020.12.020_bib10","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.prro.2018.08.002","article-title":"Hypofractionated radiation therapy for localized prostate cancer: Executive summary of an ASTRO, ASCO, and AUA evidence-based guideline","volume":"8","author":"Morgan","year":"2018","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2020.12.020_bib11","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.ijrobp.2009.02.006","article-title":"Development of RTOG consensus guidelines for the definition of the clinical target volume for postoperative conformal radiation therapy for prostate cancer","volume":"76","author":"Michalski","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2020.12.020_bib12","unstructured":"Common terminology criteria for adverse events (CTCAE) version 4.03. US Department of Health and Human Services, National Institutes of Health, National Cancer Institute. Available at: https:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/CTCAE_4.03\/CTCAE_4.03_2010-06-14_QuickReference_8.5\u00d711.pdf. Accessed June 14, 2010."},{"key":"10.1016\/j.ijrobp.2020.12.020_bib13","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1590\/S1677-5538.IBJU.2013.03.07","article-title":"Validation of the Brazilian version of the Expanded Prostate Cancer Index Composite (EPIC) for patients submitted to radical prostatectomy","volume":"39","author":"Alves","year":"2013","journal-title":"Int Braz J Urol"},{"key":"10.1016\/j.ijrobp.2020.12.020_bib14","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/j.juro.2011.04.085","article-title":"Expanded prostate cancer index composite for clinical practice: Development and validation of a practical health related quality of life instrument for use in the routine clinical care of patients with prostate cancer","volume":"186","author":"Chang","year":"2011","journal-title":"J Urol"},{"key":"10.1016\/j.ijrobp.2020.12.020_bib15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4143\/crt.2010.42.1.1","article-title":"Salvage radiotherapy for patients with PSA relapse following radical prostatectomy: Issues and challenges","volume":"42","author":"Choo","year":"2010","journal-title":"Cancer Res Treat"},{"issue":"35","key":"10.1016\/j.ijrobp.2020.12.020_bib16","doi-asserted-by":"crossref","first-page":"4158","DOI":"10.1200\/JCO.2015.63.3529","article-title":"Acute toxicity and quality of life after dose-intensified salvage radiation therapy for biochemically recurrent prostate cancer after prostatectomy: First results of the randomized trial SAKK 09\/10","volume":"33","author":"Ghadjar","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2020.12.020_bib17","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/j.ijrobp.2012.05.023","article-title":"Long-term survival and toxicity in patients treated with high-dose intensity modulated radiation therapy for localized prostate cancer","volume":"85","author":"Spratt","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2020.12.020_bib18","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/j.eururo.2019.05.011","article-title":"Patient-reported outcomes and late toxicity after postprostatectomy intensity-modulated radiation therapy","volume":"76","author":"Akthar","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.ijrobp.2020.12.020_bib19","first-page":"1009","article-title":"Is the \u03b1\/\u03b2 ratio for prostate tumours really low and does it vary with the level of risk at diagnosis?","volume":"33","author":"Fowler","year":"2013","journal-title":"Anticancer Res"},{"key":"10.1016\/j.ijrobp.2020.12.020_bib20","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.ijrobp.2015.11.025","article-title":"Image guided hypofractionated postprostatectomy intensity modulated radiation therapy for prostate cancer","volume":"94","author":"Lewis","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2020.12.020_bib21","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/0360-3016(95)00060-C","article-title":"Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC)","volume":"31","author":"Cox","year":"1995","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2020.12.020_bib22","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.ijrobp.2019.09.047","article-title":"Toxicity and biochemical outcomes of dose-intensified postoperative radiation therapy for prostate cancer: Results of a randomized phase III trial","volume":"106","author":"Qi","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2020.12.020_bib23","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/j.ijrobp.2014.07.015","article-title":"Hypofractionated IMRT of the prostate bed after radical prostatectomy: Acute toxicity in the PRIAMOS-1 trial","volume":"90","author":"Katayama","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2020.12.020_bib24","doi-asserted-by":"crossref","first-page":"e667","DOI":"10.1016\/j.clgc.2017.01.025","article-title":"Moderate hypofractionated postprostatectomy volumetric modulated arc therapy with daily image guidance (VMAT-IGRT): A mono-institutional report on feasibility and acute toxicity","volume":"15","author":"Fersino","year":"2017","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.ijrobp.2020.12.020_bib25","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/8170428","article-title":"The financial impact of hypofractionated radiation for localized prostate cancer in the United States","volume":"2019","author":"Moore","year":"2019","journal-title":"J Oncol"},{"key":"10.1016\/j.ijrobp.2020.12.020_bib26","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/s13014-019-1325-x","article-title":"Prostate bed irradiation with alternative radio-oncological approaches (PAROS)\u2013A prospective, multicenter and randomized phase III trial","volume":"14","author":"Koerber","year":"2019","journal-title":"Radiat Oncol"}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301620346666?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301620346666?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T09:54:50Z","timestamp":1759744490000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360301620346666"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":26,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["S0360301620346666"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2020.12.020","relation":{},"ISSN":["0360-3016"],"issn-type":[{"value":"0360-3016","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hypofractionated Radiation Therapy to the Prostate Bed With Intensity-Modulated Radiation Therapy (IMRT): A Phase 2 Trial","name":"articletitle","label":"Article Title"},{"value":"International Journal of Radiation Oncology*Biology*Physics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijrobp.2020.12.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}